Miloš Miljković: Our analysis of cancer drug “novelty” and cost

Miloš Miljković, Chief Medical Officer at Cartesian Therapeutics, shared a post by JAMA Network Open on Twitter, adding the following:

“As follow-up to our analysis of cancer drug efficacy versus cost, here is a look at the association between their “novelty” and cost. With Jordan Tuia, Timothée Olivier, Alyson Haslam, and Vinay Prasad.”

Quoting JAMA Network Open:

“Findings of this study indicate that the median annual price of anticancer drugs in the US is not associated with the novelty of their mechanism of action.”

For details click here.
Source: Miloš Miljković/Twitter and JAMA Network Open/Twitter